Unusual case of diarrhoea [0.03%]
Lin Han,Lu Hong,Lisha Yi et al.
Lin Han et al.
Michael Colwill,Sailish Honap,Anna-Mary Young et al.
Michael Colwill et al.
Clinical trials in IBD face difficulties of escalating complexity, high costs and challenges in recruitment. Digital twins are virtual, data-driven replicas of individual patients that model disease trajectories and treatment responses, whi...
Gefu Cai,Alex Váradi,Márk Bérchegyi et al.
Gefu Cai et al.
JOSD1 drives hepatocellular carcinoma malignancy by modulating the ubiquitination-lactylation switch on PGAM1 [0.03%]
Qing Li,Kai Yu,Suiqing Zhou et al.
Qing Li et al.
Background: Metabolic reprogramming is a hallmark of hepatocellular carcinoma (HCC), enabling rapid tumour growth and immune evasion. Protein post-translational modification (PTM) crosstalk is a critical regulator of cell...
Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability [0.03%]
Sovanlal Mukherjee,Ajith Antony,Nandakumar G Patnam et al.
Sovanlal Mukherjee et al.
Background: Failure of conventional imaging to detect pancreatic ductal adenocarcinoma (PDA) at its visually occult pre-diagnostic stage is a primary barrier to improving its otherwise poor rate of survival. ...
Metagenomic identification of gut microbiome signatures for accurate diagnosis and prognostic prediction of Epstein-Barr virus-associated nasopharyngeal carcinoma [0.03%]
Kaiqi Lan,Defeng Bai,Li Yuan et al.
Kaiqi Lan et al.
Background: Nasopharyngeal carcinoma (NPC) is strongly associated with Epstein-Barr virus (EBV) infection. The gut microbiome can influence outcomes of viral infections but the potential links among the gut microbiome, EB...
Fatima El-Assaad,Emad M El-Omar
Fatima El-Assaad
Reply to the letter to the editor from Gao and Liu regarding 'Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease' [0.03%]
Jimmy Che To Lai,Terry Cheuk-Fung Yip
Jimmy Che To Lai
The UK experience with hepatitis B immunoglobulin use following liver transplantation: wide variation in practice despite evidence supporting cost-effective HBIG-free prophylaxis [0.03%]
Almuthana Mohamed,Maria Guerra Veloz,Lindsay Greenland et al.
Almuthana Mohamed et al.
Introduction: Hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues (NA) are standard prophylaxis against hepatitis B virus (HBV) recurrence after liver transplantation (LT). However, indefinite HBIG use, with var...
Clarifying the clinical role and implementation boundaries of the clinical-radiological model for TACE-treated hepatocellular carcinoma [0.03%]
Shuang Shen,Guodong Yang,Xin Qiu
Shuang Shen